Drug intelligence / Profile preview

adsorbed acellular diphtheria, tetanus, and pertussis (component) and Haemophilus influenzae type b (conjugate) combined vaccine

Development stage: Unknown
Lead developer: Zhifei Biological
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The adsorbed acellular diphtheria, tetanus, and pertussis (component) and Haemophilus influenzae type b (conjugate) combined vaccine (DTaP-Hib) is a quadrivalent combination vaccine being developed by Zhifei Biotech (through its subsidiary Beijing Zhifei Lvzhu Biopharmaceutical). It combines acellular pertussis antigens, diphtheria toxoid, tetanus toxoid (all adsorbed), and a Haemophilus influenzae type b (Hib) polysaccharide conjugate antigen. The vaccine is designed to induce protective immunity against diphtheria, pertussis (whooping cough), tetanus, and invasive Haemophilus influenzae type b disease in infants and young children. It is currently in Phase I clinical development in China.

Other names: DTaP-Hib combined vaccineDTaP-Hib vaccineDiphtheria, Tetanus and Acellular Pertussis Adsorbed (Component) and Haemophilus Type b Conjugate VaccineDiphtheria, Tetanus and Acellular Pertussis Adsorbed (Component) and Haemophilus influenzae Type b Conjugate Vaccine吸附无细胞百白破（组分）b型流感嗜血杆菌（结合）联合疫苗组分百白破-Hib四联疫苗

Targets

Diphtheria toxinPRNP (Cellular Prion Protein)

Beyond the preview

Go deeper on adsorbed acellular diphtheria, tetanus, and pertussis (component) and Haemophilus influenzae type b (conjugate) combined vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adsorbed acellular diphtheria, tetanus, and pertussis (component) and Haemophilus influenzae type b (conjugate) combined vaccine.

Explore the full profile